Hypothyroidism and cardiovascular disease: Role of new risk factors and coagulation parameters

Seminars in Vascular Medicine

Volumn 4, Issue 2, 2004, Pages 145-151

  Jublanc, Christel ^a   Bruckert, Eric ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular disease; D dimers; Fibrinogen; Homocysteine; Hypothyroidism; Plasminogen activator inhibitor type 1; Subclinical hypothyroidism

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; THYROID HORMONE; THYROXINE;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; FIBRINOLYSIS; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; METABOLISM; REVIEW; RISK FACTOR; VON WILLEBRAND DISEASE;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HOMOCYSTEINE; HUMANS; HYPOTHYROIDISM; RISK FACTORS; THYROID HORMONES; THYROXINE; VON WILLEBRAND DISEASE;

EID: 7244236500     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835372     Document Type: Review

References (46)

1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509
2. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003;88:2438-2444
3. Perk M, O'Neill BJ. The effect of thyroid hormone therapy on angiographic coronary artery disease progression. Can J Cardiol 1997;13:273-276
4. Giannattasio C, Rivolta MR, Failla M, Mangoni AA, Stella ML, Mancia G. Large and medium sized artery abnormalities in untreated and treated hypothyroidism. Eur Heart J 1997;18:1492-1498
5. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534
6. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003;88:3731-3737
7. Nagasaki T, Inaba M, Henmi Y, et al. Change in von Willebrand factor and carotid intima-media thickness in hypothyroid patients with normal thyroid function after levothyroxine replacement therapy. Eur J Endocrinol 2004;150:125-131
8. Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JCM. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000;132:270-278
9. Willeit J, Kiechl S, Oberhollenzer F, et al. Distinct risk profiles of early and advanced atherosclerosis. Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2000;20:529-537
10. Bruckert E, Giral P, Chadarevian R, Turpin G. Low free-thyroxine are a risk factor for subclinical atherosclerosis in euthyroid hyperlipidemic patients. J Cardiovasc Risk 1999;6:327-331
11. Auer J, Berent R, Weber T, Lassnig E, Eber B. Thyroid function is associated with presence and severity of coronary atherosclerosis. Clin Cardiol 2003;26:569-573
12. Ganotakis ES, Mandalaki K, Tampakaki M, et al. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy. Angiology 2003;54:569-576
13. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy. Angiology 2003;54:569-576
14. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with sub-clinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf) 1996;44:643-649
15. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993-3001
16. Oziol L, Faure P, Bertrand N, Chomard P. Inhibition of in vitro macrophage-induced low density lipoprotein oxidation by thyroid compounds. J Endocrinol 2003;177:137-146
17. Duntas LH, Mantzou E, Koutras DA. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002;12:1003-1007
18. Muller B, Zulewski H, Huber P, Ratcliffe JG, Staub JJ. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism. N Engl J Med. 1995;333:964-969
19. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997;136:1-7
20. Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J 1990;66:280-284
21. Farid NR, Griffiths BL, Collins JR, Marshall WH, Ingram DW. Blood coagulation and fibrinolysis in thyroid disease. Thromb Haemost 1976;35:415-422
22. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999;50:655-659
23. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M, Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2003;13:971-977
24. Erem C, Kavgaci H, Ersoz HO, et al. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract 2003;57:78-81
25. Muller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ, Marbet GA. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001;31:131-137
26. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol. 2001;14:401-436
27. Levesque H, Borg JY, Cailleux N, et al. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Eur J Med 1993;2:287-288
28. Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P, Turpin G. Relationship between thyroid hormones and plasma D-Dimer levels. Thromb Haemost 1998;79:99-103
29. Thornton JG, Parapia LA, Minford AM. Hypothyroidism and Von Willebrands disease. Lancet 1987;1(8545):1314-1315
30. Myrup B, Bregengard C, Faber J. Primary haemostasis in thyroid disease. J Intern Med 1995;238:59-63
31. Erfurth EM, Ericsson UB, Egervall K, Lethagen SR. Effect of acute desmopressin and of long-term thyroxine replacement on haemostasis in hypothyroidism. Clin Endocrinol (Oxf) 1995;42:373-378
32. Chadarevian R, Bruckert E, Giral P, Turpin G. Relationship between thyroid hormones and fibrinogen levels. Blood Coagul Fibrinoltsis 1999;10:481-486
33. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247
34. Held C, Hjemdahl, Rehnqvist N, et al. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med. 1997;241:59-69
35. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:493-498
36. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001;86:732-737
37. Kohno A, Hara Y. Severe myocardial ischemia following hormone replacement in two cases of hypothyroidism with normal coronary arteriogram. Endocr J 2001;48:565-572
38. Van Oosterom AT, Kerkhoven P, Veltkamp JJ. Metabolism of the coagulation factors of the prothrombin complex in hypothyroidism in man. Thromb Haemost 1979;41:273-285
39. Stanger O, Herrmann W, Pietrzik K, et al. DACH-LIGA homocystein (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-1403
40. Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003;166:379-386
41. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol (Oxf) 2001;54:197-204
42. Lien EA, Nedrebo BG, Varhaug JE, Nygard O, Aakvaag A, Ueland PM. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metab 2000;85:1049-1053
43. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
44. Jublanc C, Bruckert E, Giral P, et al. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis 2004;172:7-11
45. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238
46. Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001;345:260-265